Anaphore Takes $13M

La Jolla-based Anaphore, a developer of protein therapeutics, announced today that it has raised an additional $13M in the firm's Series A preferred stock financing. According to the firm, the new funding brings the total round size to $38M. New investors SR One, Merck Serono Ventures, Aravis SA joined in the close. Other investors in the round included 5AM Ventures, Versant Ventures, and Apposite Capital. Anaphore said it would use the funding to extend "operating runway" and to accelerate development of its drug candidates. Dr. Simeon George of SR One joins the board in conjunction with the funding. More information »